Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Transpl Infect Dis ; 18(3): 466-70, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26992092

ABSTRACT

BACKGROUND: The polysaccharide cell wall component, 1,3-beta-D-glucan (BDG), is used as a serum biomarker for invasive fungal infection (IFI). Patients receiving hematopoietic stem cell transplantation (HSCT) are considered a highly vulnerable group for IFI development. We evaluated the diagnostic performance of serum BDG screening in HSCT recipients. METHODS: HSCT recipients were prospectively enrolled in this study between September 2014 and August 2015. Routine serum BDG screening was performed 2-3 times weekly by using the Fungitell(®) assay. All samples were classified according to the 2008 EORTC/MSG criteria, with serum BDG results not being considered for classification. The diagnostic performance of BDG testing for IFI was calculated. BDG values ≥80 pg/mL were considered positive. RESULTS: A total of 308 serum samples were collected in 45 patients. The majority of 172 samples (55.8%) were obtained at the early phase (within 30 days) after allogeneic HSCT. BDG levels were significantly higher in 16 possible/probable IFI samples when compared to no evidence for IFI samples (median 170 pg/mL, interquartile range [IQR] 100-274 pg/mL vs. median 15 pg/mL, IQR 15-15 pg/mL; P < 0.001, Mann-Whitney U-test). Diagnostic performance of serum BDG screening for possible IFI/probable invasive pulmonary aspergillosis vs. no evidence for IFI was as follows: sensitivity 81%, specificity 98%, positive predictive value 65%, negative predictive value (NPV) 99%, and diagnostic odds ratio 176 (95% confidence interval 41-761). CONCLUSIONS: Our data suggest that serum BDG testing in HSCT patients may be highly specific and associated with a very high NPV of >99%. Therefore, serum BDG may be a helpful tool to rule out IFI in HSCT patients.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Invasive Pulmonary Aspergillosis/diagnosis , beta-Glucans/blood , Adult , Aged , Diagnostic Tests, Routine , Female , Humans , Invasive Pulmonary Aspergillosis/microbiology , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Proteoglycans , ROC Curve , Sensitivity and Specificity
2.
Mycoses ; 58(12): 735-45, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26497302

ABSTRACT

The increasing incidence of invasive fungal diseases (IFD), most of all invasive aspergillosis (IA) in immunocompromised patients emphasises the need to improve the diagnostic tools for detection of fungal pathogens. We investigated the diagnostic performance of a multifungal DNA-microarray detecting 15 different fungi [Aspergillus, Candida, Fusarium, Mucor, Rhizopus, Scedosporium and Trichosporon species (spp.)] in addition to an Aspergillus specific polymerase chain reaction (PCR) assay. Biopsies, bronchoalveolar lavage and peripheral blood samples of 133 immunocompromised patients (pts) were investigated by a multifungal DNA-microarray as well as a nested Aspergillus specific PCR assay. Patients had proven (n = 18), probable (n = 29), possible (n = 48) and no IFD (n = 38) and were mostly under antifungal therapy at the time of sampling. The results were compared to culture, histopathology, imaging and serology, respectively. For the non-Aspergillus IFD the microarray analysis yielded in all samples a sensitivity of 64% and a specificity of 80%. Best results for the detection of all IFD were achieved by combining DNA-microarray and Aspergillus specific PCR in biopsy samples (sensitivity 79%; specificity 71%). The molecular assays in combination identify genomic DNA of fungal pathogens and may improve identification of causative pathogens of IFD and help overcoming the diagnostic uncertainty of culture and/or histopathology findings, even during antifungal therapy.


Subject(s)
Aspergillosis/diagnosis , Aspergillus fumigatus/isolation & purification , Multiplex Polymerase Chain Reaction/methods , Oligonucleotide Array Sequence Analysis/methods , Adult , Antifungal Agents/therapeutic use , Aspergillosis/blood , Aspergillosis/diagnostic imaging , Aspergillus fumigatus/genetics , Aspergillus fumigatus/immunology , Base Sequence , Biopsy, Needle , Bronchoalveolar Lavage , DNA, Fungal/isolation & purification , Female , Humans , Immunocompromised Host , Male , Molecular Sequence Data , Radiography , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...